• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Shiv Sagiv

    4/8/26 4:05:04 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SHIV SAGIV

    (Last)(First)(Middle)
    C/O MARPAI, INC.
    615 CHANNELSIDE DRIVE, SUITE 207

    (Street)
    TAMPA FLORIDA 33602

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Marpai, Inc. [ MRAI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    02/19/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A Common Stock02/19/2026A100,000(1)A$0.00522,000D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The restricted stock units ("RSUs") were granted pursuant to the Marpai Inc.'s (the "Company") 2024 Global Stock Incentive Plan. One-third (1/3) of the RSUs vested on February 19, 2026 (the "Effective Date"), one-third (1/3) of the RSUs vest upon the execution of a letter of intent or other comparable indication of interest approved by the Company's Board of Directors in connection with a potential strategic transaction (the "Strategic Transactions"), and the remaining one-third (1/3) of the RSUs vest upon the closing of the Strategic Transaction, in each case subject to the reporting person's continued service through the applicable vesting date.
    /s/ Sagiv Shiv04/08/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026

    TAMPA, Fla., May 26, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration ("TPA"), and Pharmacy Benefit Management ("PBM") services, today announced a historic expansion of its business book. Following a series of newly secured commitments and confirmed new business across its Third-Party Administrator (TPA) and MarpaiRx Pharmacy Benefit Management (PBM) platforms, the Company estimates a total increase of 192,000 member lives scheduled to roll out between August 2026 and January 2027.This influx represents a nearly six-fold increase in the Company's current member lives, potentially transforming

    5/26/26 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

    Strategic Investments in Operations and Technology Fuel Platform for Accelerated Growth and Aim of Second-Half 2026 ProfitabilityTAMPA, Fla., May 15, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management ("PBM") services, announced the financial results for the first quarter 2026.Marpai's first quarter 2026 results reflect the Company's continued execution of its operational transformation designed to position the business for profitability and growth. The Company has nearly completed the migration of its IT and claims processing to a single, unified cloud-bas

    5/15/26 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai, Inc. Announces Significant New Business Wins across TPA and MarpaiRx; Solidifies Forecast for Profitability

    TAMPA, Fla., May 11, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration ("TPA"), and Pharmacy Benefit Management ("PBM") services, today announced several significant new business wins across its core TPA and MarpaiRx divisions. These new client wins, representing a diverse range of self-insured employer groups, are expected to be primary drivers in the Company's path toward achieving sustained profitability.Pursuant to the newly secured contracts, Marpai is expected to provide comprehensive TPA services and integrated pharmacy benefit management services through MarpaiRx, reflect the growing de

    5/11/26 10:22:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    SEC Filings

    View All

    SEC Form 10-Q filed by Marpai Inc.

    10-Q - Marpai, Inc. (0001844392) (Filer)

    5/15/26 4:16:21 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    5/1/26 4:15:28 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-K filed by Marpai Inc.

    10-K - Marpai, Inc. (0001844392) (Filer)

    3/25/26 4:44:45 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:01:11 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Eitan Yaron bought $2,700 worth of shares (10,000 units at $0.27), increasing direct ownership by 0.92% to 1,099,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    5/22/26 4:02:13 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:02:06 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:01:11 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv returned 50,000 shares to the company and was granted 125,000 shares, decreasing direct ownership by 8% to 613,667 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    6/2/26 5:00:16 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

    Strategic Investments in Operations and Technology Fuel Platform for Accelerated Growth and Aim of Second-Half 2026 ProfitabilityTAMPA, Fla., May 15, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Third-Party Administration (TPA), and Pharmacy Benefit Management ("PBM") services, announced the financial results for the first quarter 2026.Marpai's first quarter 2026 results reflect the Company's continued execution of its operational transformation designed to position the business for profitability and growth. The Company has nearly completed the migration of its IT and claims processing to a single, unified cloud-bas

    5/15/26 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care